Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators. Harbeck N, et al. Among authors: otremba bj. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31. Breast Cancer Res Treat. 2017. PMID: 27798749 Free PMC article. Clinical Trial.
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group. Huebner G, et al. Br J Cancer. 2009 Jan 13;100(1):44-9. doi: 10.1038/sj.bjc.6604818. Epub 2008 Dec 9. Br J Cancer. 2009. PMID: 19066607 Free PMC article. Clinical Trial.
Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G; North-Eastern German Society of Gynecological Oncology. Sehouli J, et al. Cancer Chemother Pharmacol. 2009 Aug;64(3):585-91. doi: 10.1007/s00280-008-0909-1. Epub 2009 Jan 21. Cancer Chemother Pharmacol. 2009. PMID: 19156414
Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial.
Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran SE, de Wit M; PELICAN investigators. Honecker F, et al. J Geriatr Oncol. 2018 Mar;9(2):163-169. doi: 10.1016/j.jgo.2017.09.009. Epub 2017 Oct 18. J Geriatr Oncol. 2018. PMID: 29055624 Clinical Trial.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, Hasmueller S, Köhler A, Otremba B, Griesinger F, Schindlbeck C, Trojan A, Otto F, Knauer M, Pusch R, Harbeck N; WSG-PRIMe investigators in Germany, Austria, Switzerland. Wuerstlein R, et al. Breast Cancer Res Treat. 2019 Jun;175(2):389-399. doi: 10.1007/s10549-018-05075-x. Epub 2019 Feb 22. Breast Cancer Res Treat. 2019. PMID: 30796651 Free PMC article. Clinical Trial.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T, Fasching PA, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates RE, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M; PreCycle Investigators. Degenhardt T, et al. Trials. 2023 May 17;24(1):338. doi: 10.1186/s13063-023-07306-z. Trials. 2023. PMID: 37198674 Free PMC article. Clinical Trial.
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R, Sotlar K, Gluz O, Otremba B, von Schumann R, Witzel I, Schindlbeck C, Janni W, Schem C, Bauerfeind I, Hasmueller S, Tesch H, Paulenz A, Ghali N, Orujov E, Kates RE, Cowens W, Hornberger J, Pelz E, Harbeck N. Wuerstlein R, et al. Curr Med Res Opin. 2016 Jul;32(7):1217-24. doi: 10.1185/03007995.2016.1166102. Epub 2016 Mar 30. Curr Med Res Opin. 2016. PMID: 26971372
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7. Blood. 2011. PMID: 21139079 Free article.
30 results